Understanding the ECM
Decoding the ECM to unlock unprecedented therapies
Reshaping tissue fibrosis and solid tumour drug discovery
ECM remodelling is the common denominator behind fibrosis and nearly every solid tumour — by targeting it, Engitix is tackling one of the most fundamental drivers of human disease.
The ECM is massively overlooked
The study of ECM is an overlooked area of drug discovery for two key reasons:
1) The tools for studying biology at scale have not existed.
2) Most in vitro models do not begin to capture the full complexity of matrix biology.
The Engitix platform unlocks drug discovery for the ECM
Engitix is building the tools to study ECM biology at scale, including complex 3D models to recapitulate the role of matrix biology in human disease. By targeting the ECM, Engitix is addressing one of the most fundamental mechanisms underlying human disease.
Our patient-centric ECM discovery platform combines one of the world’s largest ECM bioarchives with advanced 3D human cell culture models to study the biological impact of disease-driven changes in ECM composition and structure.
Leveraging AI, machine learning, and deep learning technologies, Engitix can now decode the vast complexity of ECM data — identifying novel therapeutic targets, revealing new biomarkers, and uncovering mechanisms of action that traditional methods overlook. This data-driven approach enables us to predict therapeutic efficacy with greater accuracy and speed, transforming how candidates are prioritized and advanced toward the clinic.
By understanding and modelling how ECM dysregulation drives fibrosis, inflammation, tumour growth, and metastasis, Engitix is pioneering a new class of matrix-directed therapeutics designed to alter the course of disease and improve outcomes for patients worldwide.
The world’s first, patient-centric ECM-based drug discovery platform
Our human ECM-based discovery platform is applicable to multiple organs, indications, therapeutic strategies, and modalities.
